IP Library Granted Patent US 7,837,660
Granted Patent B2
US 7,837,660 · App. 11/957,841 · Granted Nov 23, 2010

Recessed electrodes for sensing flow in ophthalmic surgical system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,837,660
App. No.
11/957,841
Granted
Nov 23, 2010
Kind
B2
Abstract

A flow measurement device 100 is provided that includes an electrode terminal chamber 102 with an inlet 104 in communication with a flow channel 108 for receiving fluid and viscoelastic material aspirated from a surgical site, and an outlet 106 that tapers into a flow channel 108 . The outlet 108 has a taper angle that is sufficient to smooth flow and cause viscoelastic material entering the electrode terminal chamber 102 to flow substantially within a center portion of the chamber and through the outlet 106 . The electrode terminal chamber 102 further includes first and second electrode terminals 130 and 140 disposed on generally opposite sides of the electrode terminal chamber 102 in a spaced-apart manner. The first and second electrode terminals 130 and 140 are positioned a distance from the center of the chamber 102 that is sufficient to substantially avoid contact between the terminals and viscoelastic materials flowing through the chamber 102.

Claims (30)

1. An ophthalmic surgical pump system for providing control of aspiration flow rate, comprising:

an electrode terminal chamber having an inlet in communication with a flow channel for receiving fluid and viscoelastic material aspirated from a surgical site, and an outlet that tapers into a flow, the outlet having a taper angle that is sufficient to smooth flow and cause viscoelastic material entering the electrode terminal chamber to flow substantially within a center portion of the chamber and through the outlet; and

first and second electrode terminals disposed on generally opposite sides of the electrode terminal chamber in a spaced-apart manner, the first and second electrode terminals each being positioned a distance from the center of the chamber that is sufficient to substantially avoid contact with viscoelastic materials flowing through the chamber.

2. The ophthalmic surgical pump system of claim 1 , further comprising first and second recesses within the electrode terminal chamber configured to receive the first and second electrode terminals, the first and second recesses being symmetrically disposed on opposing sides of the electrode terminal chamber and spaced from the center portion of the chamber by a spacing sufficient to prevent viscoelastic material flow from impinging on the first and second electrode terminals.

3. The ophthalmic surgical pump system of claim 1 , wherein the inlet of the electrode terminal chamber includes sharp corners formed between the chamber inlet opening and the flow channel sidewalls, which guide or direct the viscoelastic material through the center of the electrode terminal chamber.

4. The ophthalmic surgical pump system of claim 3 , wherein the outlet has a tapered surface at an angle that causes the viscoelastic materials guided through the center of the chamber by the sharp corners to be substantially directed towards the outlet of the chamber, such that flow of viscoelastic materials does not impinge on either of the first and second electrode terminals.

5. The ophthalmic surgical pump system of claim 1 , wherein said aspirated fluid comprises an electrically conductive saline solution, and the first and second electrode terminals are arranged opposite one another in a spaced-apart relationship sufficient to generate at least one electrical signal indicative of the flow rate of said fluid flowing through the electrode terminal chamber.

6. The ophthalmic surgical pump system of claim 1 , wherein the electrode terminal chamber and flow channel form a disposable electrode assembly that is adapted to connect to an ophthalmic surgical pump system, and the first and second electrodes provide at least one signal indicative of the flow rate of fluid flowing through the disposable electrode assembly.

7. The ophthalmic surgical pump system of claim 1 , wherein the first and second electrode terminals are plated with a corrosion resistant electrically-conductive metal.

8. An ophthalmic surgical pump system for providing control of aspiration flow rate, comprising:

a disposable electrode assembly including a flow channel having an inlet for receiving fluid, tissue, and viscoelastic material aspirated from a surgical site, and an outlet;

an electrode terminal chamber disposed between the flow channel inlet and outlet, the electrode terminal chamber having an outlet end that tapers into the flow channel, said outlet end having a taper that is sufficient to smooth flow and cause viscoelastic material entering the electrode terminal chamber to flow substantially within a center portion of the chamber and through the outlet;

first and second electrode terminals disposed on generally opposite sides of the electrode terminal chamber in a spaced-apart manner, the first and second electrode terminals each being positioned at a distance from the center of the chamber that is sufficient to substantially avoid contact between the first and second electrode terminals and viscoelastic materials flowing through the chamber's center portion; and

wherein the disposable electrode assembly is incorporated in a collection cassette.

9. The ophthalmic surgical pump system of claim 8 , further comprising first and second recesses within the electrode terminal chamber configured to receive the first and second electrode terminals, the first and second recesses being symmetrically disposed on opposing sides of the electrode terminal chamber and spaced from the center portion of the chamber by a spacing sufficient to prevent viscoelastic material flow from impinging on the first and second electrode terminals.

10. The ophthalmic surgical pump system of claim 8 , wherein the chamber outlet is vertically oriented above the chamber inlet, the chamber outlet including a tapered portion at an angle relative to the flow channel that is sufficient to establish a laminar flow region for directing viscoelastic material through a center portion of the chamber, such that flow of viscoelastic materials does not impinge on either of the first and second electrode terminals.

11. The ophthalmic surgical pump system of claim 8 , wherein the inlet of the electrode terminal chamber includes sharp corners formed between the chamber inlet opening and the flow channel sidewalls, which guide or direct the viscoelastic material through the center of the electrode terminal chamber.

12. The ophthalmic surgical pump system of claim 11 , wherein the outlet has a tapered surface at an angle that causes the viscoelastic materials guided through the center of the chamber by the sharp corners to be substantially directed towards the outlet of the chamber, such that flow of viscoelastic materials does not impinge on either of the first and second electrode terminals.

13. The ophthalmic surgical pump system of claim 8 , wherein said fluid comprises an electrically conductive saline solution, and the first and second electrode terminals are arranged opposite one another in a spaced-apart relationship sufficient to generate at least one electrical signal indicative of the flow rate of said fluid flowing through the electrode terminal chamber.

14. The ophthalmic surgical pump system of claim 8 , wherein the electrode terminal chamber and flow channel form a disposable electrode assembly that is adapted to connect to an ophthalmic surgical pump system, and the first and second electrodes provide at least one signal indicative of the flow rate of fluid flowing through the disposable electrode assembly.

15. The ophthalmic surgical pump system of claim 8 , wherein the first and second electrode terminals are plated with a corrosion resistant electrically-conductive metal.

16. An ophthalmic surgical pump system for providing control of aspiration flow rate, comprising:

an electrode assembly including an electrode terminal chamber therein, and a flow channel extending through the electrode terminal chamber for receiving fluid and viscoelastic material that is aspirated from a surgical site, wherein the electrode terminal chamber includes a first recessed area spaced from the flow channel extending through the electrode terminal chamber, a second recessed area spaced from the flow channel extending through the electrode terminal chamber, and an outlet end that tapers into the flow channel, said outlet end having a taper that is sufficient to direct the flow of viscoelastic material through the center of the chamber and away from the first and second recessed areas;

a first electrode terminal made of a corrosion resistant electrically-conductive metal, disposed within the first recessed area proximate to and spaced a distance from the flow channel;

a second electrode terminal made of a corrosion resistant electrically-conductive metal, disposed within the second recessed area, proximate to and spaced a distance from the flow channel; and

wherein the first electrode terminal and second electrode terminal are spaced at a distance that is sufficient to avoid flow of viscoelastic material passing through the chamber, such that flow of viscoelastic materials does not impinge on either of the first and second electrode terminals.

17. The ophthalmic surgical pump system of claim 16 , wherein the first and second recesses are symmetrically disposed on opposing sides of the electrode terminal chamber and flow channel extending through the chamber.

18. The ophthalmic surgical pump system of claim 17 , wherein the inlet of the electrode terminal chamber includes sharp corners formed between the chamber inlet opening and the flow channel sidewalls, which guide or direct the viscoelastic material through the center of the electrode terminal chamber.

19. The ophthalmic surgical pump system of claim 18 , wherein the outlet has a tapered surface at an angle that causes the viscoelastic materials guided through the center of the chamber by the sharp corners to be substantially directed towards the outlet of the chamber, such that flow of viscoelastic materials does not impinge on either of the first and second electrode terminals.

20. The ophthalmic surgical pump system of claim 17 , wherein said fluid comprises an electrically conductive saline solution, and the first and second electrode terminals are arranged opposite one another in a spaced-apart relationship sufficient to generate at least one electrical signal indicative of the flow rate of said fluid flowing through the electrode terminal chamber.

Assignments (30)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 043251/0932) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061872/0099 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 031156/0508) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061778/0446 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 034749/0689) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; UNIVERSITY OF ROCHESTER
Reel/Frame 061778/0146 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Mar 21, 2011
From: WP PRISM INC.; BAUSCH & LOMB INCORPORATED
To: CREDIT SUISSE AG, AS ADMINISTRATIVE AGENT
Reel/Frame 025990/0222 →
SECURITY AGREEMENT Recorded Mar 26, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC
To: CREDIT SUISSE
Reel/Frame 020733/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2008
From: JONES, ROSS PETER; LUTWYCHE, MARK IAN; POOLEY, DAVID MARTIN
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 020574/0696 →